Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. lifted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 15.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,707 shares of the specialty pharmaceutical company’s stock after buying an additional 631 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Jazz Pharmaceuticals were worth $579,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Covestor Ltd increased its holdings in Jazz Pharmaceuticals by 676.5% in the 3rd quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock worth $51,000 after acquiring an additional 345 shares in the last quarter. Spire Wealth Management increased its stake in shares of Jazz Pharmaceuticals by 128.6% during the third quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 238 shares in the last quarter. Headinvest LLC acquired a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $56,000. Signaturefd LLC lifted its stake in Jazz Pharmaceuticals by 85.7% in the 3rd quarter. Signaturefd LLC now owns 546 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 252 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter worth about $78,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Transactions at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now directly owns 8,364 shares in the company, valued at approximately $1,000,668.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CAO Patricia Carr sold 1,936 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Philip L. Johnson bought 12,000 shares of the business’s stock in a transaction on Friday, March 1st. The stock was purchased at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the transaction, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The disclosure for this purchase can be found here. Company insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $107.43 on Friday. The firm has a 50 day simple moving average of $118.60 and a 200-day simple moving average of $121.94. The stock has a market cap of $6.77 billion, a price-to-earnings ratio of 17.55, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.24 and a quick ratio of 1.85. Jazz Pharmaceuticals plc has a 1-year low of $106.61 and a 1-year high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. On average, analysts expect that Jazz Pharmaceuticals plc will post 16.24 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on JAZZ. HC Wainwright decreased their target price on Jazz Pharmaceuticals from $204.00 to $200.00 and set a “buy” rating on the stock in a research report on Thursday, March 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $180.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $220.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Barclays reduced their target price on shares of Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, March 1st. Finally, Piper Sandler raised their price target on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $195.08.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.